ArticleOncotarget2017
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.BMC nephrology · 2020Pooled it
- Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure.Pediatric nephrology (Berlin, Germany) · 2026Article
- Efficacy and Safety of Rituximab in Treating Adult Patients with Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Prospective Study Compared with Glucocorticoids.Drug design, development and therapy · 2025Article
- Article
- The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult.Kidney international reports · 2022Article
- A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome.International urology and nephrology · 2022Article
- Rituximab Dosing in Glomerular Diseases: A Scoping Review.Canadian journal of kidney health and disease · 2022Article
- Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Journal of clinical medicine · 2021Review
- Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.BMC nephrology · 2021Article
- Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.Clinical kidney journal · 2021Review
- Thrombotic microangiopathy triggered by podocytopathy.Clinical nephrology. Case studies · 2021Article
- Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.Drug design, development and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have described our experience treating 6 FSGS and 9 MCD patients with steroid-dependent/refractory nephrotic syndrome (NS) with RTX. Patients received RTX (375 mg/m2) intravenously on days 1, 8, 23, and 29. During a median follow-up of 8 months (range, 3-36 months) after RTX administration, all patients achieved complete or partial remission. Relapses decreased by approximately 30-fold compared with the year preceding RTX treatment, and an 89.27% reduction in proteinuria was observed. Furthermore, RTX treatment could decrease medical costs by 76.52% compared with the costs associated with the long-term use (for 12-13 months) of steroids and immunosuppressive drugs. In conclusion, RTX treatment was safe and effective for patients with refractory FSGS or MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.